Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

DYN

Dyne Therapeutics Inc

Apr 28 • 04:00PM ET

18.16

+0.12 0.67 %

Healthcare • Biotechnology • USA • Mid • NASD

Apr 27, 4:40 PMDyne Therapeutics reports preclinical FORCE platform data showing robust MAPT RNA knockdown and CNS activity in mice and nonhuman primates

Peers: BIIB VRTX CRSP ALNY BMRN RARE NTLA SRPT EDIT BLUE

| Held by: VTI XBI IWM VB VXF VBR IBB IWN SCHA VTWO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.54	Insider Own	22.66%	Shs Outstand	164.95M	Perf Week	-5.47%
Market Cap	3.00B	Forward P/E	-	EPS next Y	-3.09	Insider Trans	-6.24%	Shs Float	127.79M	Perf Month	5.95%
Enterprise Value	2.06B	PEG	-	EPS next Q	-0.77	Inst Own	91.28%	Short Float	16.98%	Perf Quarter	0.67%
Income	-446.21M	P/S	-	EPS this Y	8.96%	Inst Trans	9.70%	Short Ratio	10.24	Perf Half Y	6.07%
Sales	0.00M	P/B	3.08	EPS next Y	2.11%	ROA	-47.52%	Short Interest	21.70M	Perf YTD	-7.16%
Book/sh	5.89	P/C	2.70	EPS next 5Y	13.20%	ROE	-55.71%	52W High	25.00 -27.36%	Perf Year	60.99%
Cash/sh	6.72	P/FCF	-	EPS past 3/5Y	-2.41% 3.39%	ROIC	-39.27%	52W Low	8.06 125.31%	Perf 3Y	75.29%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.54% 5.65%	Perf 5Y	-4.27%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-5.72%	Oper. Margin	-	ATR (14)	1.11	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	22.25	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	46.20	Recom	1.31
Dividend Gr. 3/5Y	- -	Current Ratio	22.25	EPS Q/Q	13.34%	SMA20	-4.26%	Beta	1.11	Target Price	38.19
Payout	-	Debt/Eq	0.17	Sales Q/Q	-	SMA50	2.43%	Rel Volume	1.00	Prev Close	18.04
Employees	258	LT Debt/Eq	0.17	Earnings	Mar 02 BMO	SMA200	10.54%	Avg Volume	2.12M	Price	18.16
IPO	Sep 17, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	0.34% -	Trades		Volume	2,127,329	Change	0.67%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-10-25	Upgrade	Oppenheimer	Perform → Outperform	$40
Oct-10-25	Downgrade	Oppenheimer	Outperform → Perform
Aug-25-25	Upgrade	Raymond James	Outperform → Strong Buy	$35
Jun-24-25	Initiated	Bernstein	Mkt Perform	$13
Jun-11-25	Resumed	Raymond James	Outperform	$37
Jun-02-25	Resumed	Oppenheimer	Outperform	$34
May-29-25	Initiated	Evercore ISI	Outperform	$46
Mar-12-25	Initiated	BMO Capital Markets	Outperform	$50
Mar-07-25	Initiated	Scotiabank	Sector Outperform	$50
Dec-13-24	Initiated	Robert W. Baird	Outperform	$46
Nov-26-24	Initiated	RBC Capital Mkts	Outperform	$45
Oct-24-24	Downgrade	JP Morgan	Overweight → Neutral	$43 → $35
May-21-24	Reiterated	Chardan Capital Markets	Buy	$31 → $42
Apr-30-24	Initiated	Morgan Stanley	Overweight	$40
Feb-20-24	Initiated	H.C. Wainwright	Buy	$36
Feb-27-23	Upgrade	Raymond James	Outperform → Strong Buy	$16 → $27
Feb-15-23	Initiated	Oppenheimer	Outperform	$34
Jan-26-23	Initiated	Guggenheim	Buy	$33
Jul-20-22	Initiated	Chardan Capital Markets	Buy	$17
Jul-12-22	Initiated	Raymond James	Outperform	$15

Show Previous Ratings

Apr-27-26 04:34PM	Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE Platform at 2026 ASGCT Annual Meeting (GlobeNewswire)
Apr-23-26 04:05PM	Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-01-26 07:30AM	Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines (GlobeNewswire)
Mar-10-26 09:47PM	Dyne Therapeutics (DYN) Climbs 11.8% on Triple-Digit Price Target Upgrade (Insider Monkey) +11.81%
Mar-08-26 06:01PM	Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1) (GlobeNewswire)
06:00PM	Loading…
06:00PM	Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) (GlobeNewswire)
Mar-02-26 07:30AM	Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
Feb-26-26 05:52AM	Sarepta CEO To Jump Ship After 'Tumultuous' Year (Benzinga)
Feb-25-26 07:30AM	Dyne Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-22-26 04:00PM	Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference (GlobeNewswire)
Feb-18-26 07:38PM	Bullish Analyst Opinion on Dyne (DYNE) Follows Rare Disease Drug Progress in Japan (Insider Monkey)
Feb-16-26 12:23PM	Dyne Therapeutics (DYN) Attains Orphan Drug Designation From Japanese Ministry (Insider Monkey)
Jan-27-26 09:16AM	Keros Therapeutics vs. Dyne: Which DMD Biotech Has More Upside? (Zacks)
Jan-20-26 07:30AM	Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (GlobeNewswire)
Jan-15-26 11:35AM	Analysts Project 120% Upside To Dyne Therapeutics, Inc. (DYN) (Insider Monkey) -5.90%
12:00PM	Loading…
Jan-12-26 12:00PM	Funding for Risky Biotechs Is Returning (The Wall Street Journal)
Jan-07-26 07:30AM	Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +7.01%
Dec-23-25 07:30AM	Dyne Therapeutics Appoints Vikram Karnani to Board of Directors (GlobeNewswire)
Dec-22-25 06:50AM	Why Analysts See a Huge Upside for Dyne Therapeutics (DYN) (Insider Monkey)
Dec-11-25 04:05PM	Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares (GlobeNewswire)
07:44AM	Dyne Therapeutics Shares Rise After Announcing Positive Topline Results for z-rostudirsen in Phase 1/2 DMD Trial (Insider Monkey)
Dec-10-25 06:20PM	Why Dyne Therapeutics Stock Was a Big Winner on Wednesday (Motley Fool) +6.78%
09:40AM	Amazon initiated, GE Vernova upgraded: Wall Street's top analyst calls (The Fly)
Dec-09-25 09:42PM	Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock (GlobeNewswire) -16.94%
06:42PM	Why Dyne Therapeutics Stock Tanked on Tuesday (Motley Fool)
04:54PM	Biggest Market Movers Today, Dec. 9: WRBY, DYN, & More (Motley Fool)
02:22PM	Dyne Therapeutics (DYN) Climbs 9.5% on Stellar Results for DMD Therapy Candidate (Insider Monkey)
01:34PM	Dyne to seek accelerated approval of DMD drug on Phase I/II data (Clinical Trials Arena)
Dec-08-25 04:02PM	Dyne Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) +9.47%
03:07PM	Why Dyne Therapeutics Stock Was Blasting Higher Today (Motley Fool)
06:30AM	Loading…
06:30AM	Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) (GlobeNewswire)
05:32AM	Dyne to seek Duchenne drug approval; Kymera, Wave and Structure shares soar (BioPharma Dive)
Dec-07-25 11:00AM	Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET (GlobeNewswire)
Nov-30-25 12:26AM	Bernstein Sees Favorable Risk-Reward for Dyne Therapeutics (DYN) Ahead of Major DYN-251 Data Release (Insider Monkey)
Nov-21-25 03:43PM	Why Dyne Therapeutics Stock Was Crushing it This Week (Motley Fool) +5.27%
Nov-05-25 04:10PM	Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) -12.89%
Nov-03-25 07:30AM	Dyne Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) +6.78%
Oct-28-25 05:24AM	Dyne (DYN) Jumps 41% as Jefferies Bets Firm to Benefit from Novartis-Avidity Merger (Insider Monkey)
Oct-27-25 06:17PM	Why Dyne Therapeutics Stock Crushed the Market on Monday (Motley Fool) +41.18%
04:54PM	This biotech's stock soared as investors look for the next buyout target (MarketWatch)
12:07PM	Why Avidity Biosciences And Dyne Therapeutics Stocks Soared 40% Monday (Investopedia)
05:26AM	Dyne, Avidity stocks soar as Novartis strikes $12 bln biotech deal (Investing.com)
04:39AM	Jefferies sees Dyne as key beneficiary of Novartis Avidity buyout (Investing.com)
Oct-16-25 04:33PM	Dyne's Zeleciment Basivarsen Shows Sustained Gains in DM1 Trial at One Year (Insider Monkey)
Oct-06-25 06:01PM	Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) (GlobeNewswire) +10.28%
Oct-04-25 04:54PM	Dyne's Investigational DMD Drug DYNE-251 Gets Japan Orphan Drug Status After Strong Trial Data (Insider Monkey)
Oct-02-25 04:05PM	Dyne Therapeutics Appoints Brian Posner to its Board of Directors (GlobeNewswire)
Sep-29-25 08:35AM	Dyne Therapeutics Receives Orphan Drug Designation in Japan for DYNE-251 in Duchenne Muscular Dystrophy (GlobeNewswire) -5.93%
Sep-10-25 12:20AM	Raymond James Increases PT on Dyne Therapeutics Stock from $31 to $35, Maintains Buy Rating (Insider Monkey)
Aug-27-25 07:30AM	Dyne Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-20-25 12:13AM	Morgan Stanley Reiterates a Buy Rating on Dyne Therapeutics (DYN), Keeps the PT (Insider Monkey)
Aug-17-25 11:41PM	Dyne Therapeutics Receives FDA Breakthrough Therapy Designation for Duchenne Muscular Dystrophy Therapy (Insider Monkey)
Aug-06-25 12:00PM	Avidity Biosciences stock soars on Novartis takeover approach report (Investing.com) +10.70%
Aug-04-25 07:30AM	Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD) (GlobeNewswire)
Jul-31-25 09:55AM	Does Dyne Therapeutics (DYN) Have the Potential to Rally 285.57% as Wall Street Analysts Expect? (Zacks)
Jul-28-25 04:10PM	Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) -6.43%
Jul-16-25 07:00AM	Satellos Appoints Dr. Wildon Farwell as Chief Medical Officer (Business Wire) +12.68%
Jul-11-25 11:27AM	RBC Capital Maintains a Buy Rating on Dyne Therapeutics (DYN) With a $25 PT (Insider Monkey)
Jul-02-25 04:01PM	Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares (GlobeNewswire)
Jun-30-25 09:45PM	Dyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common Stock (GlobeNewswire) -8.82%
04:05PM	Dyne Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
04:01PM	Dyne Therapeutics Secures Up to $275 Million in Debt Financing from Hercules Capital (GlobeNewswire)
Jun-24-25 12:46PM	Dyne Therapeutics Receives FDA Breakthrough Therapy Designation for DM1 Drug DYNE-101 (Insider Monkey)
Jun-18-25 09:45AM	Dyne at attractive entry point following pullback, says Chardan (TipRanks)
Jun-17-25 07:00AM	Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting (GlobeNewswire) -21.42%
Jun-16-25 04:05PM	Dyne Therapeutics to Host Investor Conference Call and Webcast to Provide Update on DYNE-101 for Myotonic Dystrophy Type 1, Tomorrow Tuesday, June 17 at 8:00 a.m. ET (GlobeNewswire)
Jun-05-25 07:30AM	Dyne Therapeutics to Present New Preclinical Data in Facioscapulohumeral Muscular Dystrophy at the FSHD Society International Research Congress (GlobeNewswire)
May-08-25 07:30AM	Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) +20.16%
Apr-25-25 05:05AM	EC grants orphan drug designation to Dyne Therapeutics DMD therapy (Pharmaceutical Technology)
Apr-24-25 07:30AM	Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy (GlobeNewswire)
Apr-21-25 04:09PM	Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost (Investor's Business Daily) +14.20% +6.22%
Apr-15-25 07:30AM	Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments (GlobeNewswire) +5.09%
Apr-14-25 04:30PM	Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.11%
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks) -11.76%
Mar-30-25 03:50AM	abrdn Life Sciences Investors Q4 2024 Commentary (Seeking Alpha)
Mar-28-25 09:00AM	RNA Biotechs: Current State And Outlook (Seeking Alpha)
Mar-20-25 04:30PM	Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer (GlobeNewswire)
04:19PM	Dyne Therapeutics appoints Erick Lucera as CFO (SeekingAlpha)
04:10PM	Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer (GlobeNewswire)
Mar-16-25 07:00PM	Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months (GlobeNewswire)
Mar-12-25 03:05PM	Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks (Benzinga)
01:12PM	BMO Capital Initiates Coverage on Dyne Therapeutics With Outperform Rating (GuruFocus.com)
Mar-11-25 07:30AM	Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum (GlobeNewswire)
Feb-27-25 07:30AM	Dyne Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Feb-14-25 04:05PM	Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference (GlobeNewswire)
Feb-13-25 09:35AM	After Plunging -10.43% in 4 Weeks, Here's Why the Trend Might Reverse for Dyne Therapeutics (DYN) (Zacks)
Feb-06-25 09:39AM	Dyne Therapeutics, Inc. (DYN): Among the Best Rebound Stocks to Invest In Now (Insider Monkey) +6.89%
Feb-03-25 07:30AM	Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-28-25 09:35AM	Down -42.2% in 4 Weeks, Here's Why Dyne Therapeutics (DYN) Looks Ripe for a Turnaround (Zacks)
Jan-21-25 07:30AM	Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1 (GlobeNewswire)
Jan-10-25 06:30AM	Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for DYNE-101 in DM1 in H1 2026 (GlobeNewswire) -31.15%
Jan-09-25 07:30AM	Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-08-25 04:05PM	Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET (GlobeNewswire) -31.15%
Nov-22-24 06:43AM	Dyne Therapeutics Inc. (DYN): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts (Insider Monkey)
Nov-12-24 07:30AM	Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-07-24 04:15PM	Dyne Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Oct-09-24 07:30AM	Dyne Therapeutics Presents Data at World Muscle Society Congress Highlighting Promise of FORCE Platform to Address Underlying Causes of Neuromuscular Diseases (GlobeNewswire)
Oct-07-24 05:32PM	Dyne Therapeutics, Inc. (DYN): A Hot Stock to Buy Now (Insider Monkey)
Sep-23-24 08:56AM	Dyne Therapeutics to Present at Chardan's 8th Annual Genetic Medicines Conference (GlobeNewswire) -5.36%
Sep-04-24 09:10AM	Dyne Called Its Sarepta-Rivaling Results 'Unprecedented,' But Shares Dive On C-Suite Changes (Investor's Business Daily) +5.70%

Dyne Therapeutics, Inc. is a clinical-stage company, which engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Atlas Venture Opportunity Fund	Shareholder	Apr 28 '26	Proposed Sale	18.04	47,103	849,738		Apr 28 04:44 PM
Atlas Venture Fund XI, LP	Shareholder	Apr 28 '26	Proposed Sale	18.04	119,167	2,149,773		Apr 28 04:43 PM
Atlas Venture Opportunity Fund	Shareholder	Apr 28 '26	Proposed Sale	18.04	59,836	1,079,441		Apr 28 04:43 PM
Atlas Venture Associates XI, L	Shareholder	Apr 28 '26	Proposed Sale	18.04	1,171	21,125		Apr 28 04:42 PM
Rhodes Jason P	Director	Apr 27 '26	Sale	18.15	173,493	3,148,898	9,682	Apr 27 06:15 PM
Rhodes Jason P	Director	Apr 24 '26	Sale	18.48	137,948	2,549,279	10,576	Apr 27 06:15 PM
Rhodes Jason P	Director	Apr 23 '26	Sale	19.19	73,108	1,402,943	11,286	Apr 27 06:15 PM
Atlas Venture Opportunity Fund	Shareholder	Apr 27 '26	Proposed Sale	18.26	45,709	834,646		Apr 27 04:49 PM
Atlas Venture Opportunity Fund	Shareholder	Apr 27 '26	Proposed Sale	18.26	35,947	656,392		Apr 27 04:48 PM
Atlas Venture Fund XI, LP	Shareholder	Apr 27 '26	Proposed Sale	18.26	90,943	1,660,619		Apr 27 04:48 PM
Atlas Venture Associates XI, L	Shareholder	Apr 27 '26	Proposed Sale	18.26	894	16,324		Apr 27 04:48 PM
Atlas Venture Opportunity Fund	Shareholder	Apr 24 '26	Proposed Sale	18.90	28,583	540,219		Apr 24 04:47 PM
Atlas Venture Opportunity Fund	Shareholder	Apr 24 '26	Proposed Sale	18.90	36,345	686,920		Apr 24 04:46 PM
Atlas Venture Fund XI, LP	Shareholder	Apr 24 '26	Proposed Sale	18.90	72,310	1,366,659		Apr 24 04:46 PM
Atlas Venture Associates XI, L	Shareholder	Apr 24 '26	Proposed Sale	18.90	710	13,419		Apr 24 04:45 PM
Atlas Venture Opportunity Fund	Shareholder	Apr 23 '26	Proposed Sale	19.67	15,148	297,961		Apr 23 04:46 PM
Atlas Venture Opportunity Fund	Shareholder	Apr 23 '26	Proposed Sale	19.67	19,261	378,864		Apr 23 04:45 PM
Atlas Venture Fund XI, LP	Shareholder	Apr 23 '26	Proposed Sale	19.67	38,322	753,794		Apr 23 04:45 PM
Atlas Venture Associates XI, L	Shareholder	Apr 23 '26	Proposed Sale	19.67	377	7,416		Apr 23 04:45 PM
Kersten Dirk	Director	Apr 21 '26	Sale	20.01	8,300	166,120	4,199,225	Apr 23 04:15 PM
Kersten Dirk	Director	Apr 22 '26	Sale	20.00	2,652	53,049	4,196,573	Apr 23 04:15 PM
Rhodes Jason P	Director	Apr 22 '26	Sale	19.68	287,956	5,666,974	11,663	Apr 22 06:27 PM
Rhodes Jason P	Director	Apr 20 '26	Sale	20.06	272,049	5,457,303	14,561	Apr 22 06:27 PM
Rhodes Jason P	Director	Apr 21 '26	Sale	19.52	274,297	5,353,111	13,148	Apr 22 06:27 PM
Atlas Venture Opportunity Fund	Shareholder	Apr 22 '26	Proposed Sale	19.21	59,663	1,146,126		Apr 22 04:54 PM
Atlas Venture Opportunity Fund	Shareholder	Apr 22 '26	Proposed Sale	19.21	75,866	1,457,386		Apr 22 04:53 PM
Atlas Venture Fund XI, LP	Shareholder	Apr 22 '26	Proposed Sale	19.21	150,942	2,899,596		Apr 22 04:53 PM
Atlas Venture Associates XI, L	Shareholder	Apr 22 '26	Proposed Sale	19.21	1,485	28,527		Apr 22 04:52 PM
Atlas Venture Fund XI, LP	Shareholder	Apr 21 '26	Proposed Sale	20.02	143,749	2,877,855		Apr 21 04:54 PM
Atlas Venture Opportunity Fund	Shareholder	Apr 21 '26	Proposed Sale	20.02	56,820	1,137,536		Apr 21 04:53 PM
Atlas Venture Opportunity Fund	Shareholder	Apr 21 '26	Proposed Sale	20.02	72,315	1,447,746		Apr 21 04:53 PM
Atlas Venture Associates XI, L	Shareholder	Apr 21 '26	Proposed Sale	20.02	1,413	28,288		Apr 21 04:53 PM
Kersten Dirk	Director	Apr 17 '26	Sale	20.29	211,974	4,301,292	4,332,799	Apr 21 04:15 PM
Kersten Dirk	Director	Apr 20 '26	Sale	20.07	125,274	2,513,898	4,207,525	Apr 21 04:15 PM
Atlas Venture Fund XI, LP	Shareholder	Apr 20 '26	Proposed Sale	20.41	142,571	2,909,874		Apr 20 04:44 PM
Atlas Venture Opportunity Fund	Shareholder	Apr 20 '26	Proposed Sale	20.41	56,355	1,150,206		Apr 20 04:44 PM
Atlas Venture Opportunity Fund	Shareholder	Apr 20 '26	Proposed Sale	20.41	71,722	1,463,846		Apr 20 04:44 PM
Atlas Venture Associates XI, L	Shareholder	Apr 20 '26	Proposed Sale	20.41	1,401	28,594		Apr 20 04:43 PM
Kersten Dirk	Director	Apr 15 '26	Sale	20.27	81,840	1,659,044	4,562,546	Apr 17 04:05 PM
Kersten Dirk	Director	Apr 16 '26	Sale	20.71	17,773	368,114	4,544,773	Apr 17 04:05 PM
Lucera Erick	Chief Financial Officer	Apr 01 '26	Sale	18.64	5,727	106,751	125,373	Apr 03 04:10 PM
Posner Brian S	Director	Mar 30 '26	Buy	17.08	2,000	34,160	15,500	Apr 01 04:27 PM
Lucera Erick	Officer	Apr 01 '26	Proposed Sale	18.64	5,727	106,758		Apr 01 04:06 PM
Posner Brian S	Director	Mar 11 '26	Buy	19.35	2,000	38,700	13,500	Mar 13 04:46 PM
Kersten Dirk	Director	Mar 11 '26	Sale	19.52	129,672	2,530,562	4,644,386	Mar 13 04:35 PM
Kersten Dirk	Director	Mar 10 '26	Sale	19.57	511,098	10,000,327	4,774,058	Mar 11 05:27 PM
Kersten Dirk	Director	Mar 09 '26	Sale	17.72	177,690	3,148,987	5,285,156	Mar 11 05:27 PM
ForDyne B.V.	Affiliate	Mar 11 '26	Proposed Sale	19.75	807,295	15,944,076		Mar 11 04:05 PM
Posner Brian S	Director	Mar 06 '26	Buy	15.06	3,000	45,180	11,500	Mar 10 05:33 PM
ForDyne B.V.	Affiliate	Mar 09 '26	Proposed Sale	17.72	807,295	14,306,720		Mar 09 04:09 PM
Friedl-Naderer Johanna	Chief Commercial Officer	Mar 05 '26	Sale	14.90	148	2,205	154,581	Mar 06 04:10 PM
Kerr Douglas	Chief Medical Officer	Mar 05 '26	Sale	14.90	904	13,470	171,606	Mar 06 04:09 PM
Cox John	CEO & President	Mar 05 '26	Sale	14.90	2,732	40,707	374,145	Mar 06 04:08 PM
Cox John	Officer	Mar 05 '26	Proposed Sale	14.90	2,732	40,707		Mar 05 04:06 PM
Kerr Douglas	Officer	Dec 05 '25	Proposed Sale	20.72	880	18,231		Dec 05 04:56 PM
Cox John	Officer	Dec 05 '25	Proposed Sale	20.72	2,662	55,150		Dec 05 04:55 PM
Cox John	CEO & President	Dec 05 '25	Sale	20.72	2,662	55,157	196,877	Dec 05 04:11 PM
Kerr Douglas	Chief Medical Officer	Dec 05 '25	Sale	20.72	880	18,234	87,510	Dec 05 04:09 PM
Friedl-Naderer Johanna	Chief Commercial Officer	Dec 05 '25	Sale	20.72	144	2,984	94,729	Dec 05 04:08 PM
Cox John	CEO & President	Sep 05 '25	Sale	13.41	2,640	35,402	199,539	Sep 09 04:31 PM
Friedl-Naderer Johanna	Chief Commercial Officer	Sep 04 '25	Sale	13.27	894	11,863	95,017	Sep 08 04:06 PM
Friedl-Naderer Johanna	Chief Commercial Officer	Sep 05 '25	Sale	13.41	144	1,931	94,873	Sep 08 04:06 PM
Kerr Douglas	Chief Medical Officer	Sep 04 '25	Sale	13.27	3,552	47,135	89,263	Sep 08 04:03 PM
Kerr Douglas	Chief Medical Officer	Sep 05 '25	Sale	13.41	873	11,707	88,390	Sep 08 04:03 PM
Cox John	Officer	Sep 05 '25	Proposed Sale	13.41	2,640	35,404		Sep 05 04:14 PM
Kerr Douglas	Officer	Sep 04 '25	Proposed Sale	13.27	4,552	60,402		Sep 04 04:45 PM
Cox John	CEO & President	Jul 14 '25	Buy	9.11	100,000	911,000	242,179	Jul 15 05:11 PM
Scalzo Richard William	Officer	Jun 11 '25	Proposed Sale	14.75	1,330	19,619		Jun 11 04:30 PM
Beskrovnaya Oxana	Officer	Jun 11 '25	Proposed Sale	14.75	2,132	31,449		Jun 11 04:29 PM
Cox John	CEO & President	Jun 05 '25	Sale	13.35	4,060	54,201	142,179	Jun 06 04:07 PM
Kerr Douglas	Chief Medical Officer	Jun 05 '25	Sale	13.35	1,342	17,916	92,815	Jun 06 04:05 PM
Friedl-Naderer Johanna	Chief Commercial Officer	Jun 05 '25	Sale	13.35	146	1,949	95,911	Jun 06 04:03 PM
Kerr Douglas	Officer	Jun 05 '25	Proposed Sale	13.35	1,342	17,911		Jun 05 04:13 PM
Cox John	Officer	Jun 05 '25	Proposed Sale	13.35	4,060	54,186		Jun 05 04:11 PM
Scalzo Richard William	Officer	Jun 05 '25	Proposed Sale	13.35	914	12,198		Jun 05 04:09 PM
Beskrovnaya Oxana	Officer	Jun 05 '25	Proposed Sale	13.35	1,093	14,587		Jun 05 04:07 PM
Scalzo Richard William	Officer	May 16 '25	Proposed Sale	11.82	2,479	29,313		May 16 04:10 PM
Beskrovnaya Oxana	Officer	May 16 '25	Proposed Sale	11.82	2,589	30,614		May 16 04:09 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

DYN

Dyne Therapeutics Inc

Upgrade your Finviz experience